Functional role of miRNA in cardiac resynchronization therapy

Papers of special note have been highlighted as: • of interest

References

• 1 Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling – concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J. Am. Coll. Cardiol. 35(3), 569–582 (2000).
  Medline CASGoogle Scholar
• 2 Bouvagnet P, Leger J, Dechesne CA, Dureau G, Anoal M, Leger JJ. Local changes in myosin types in diseased human atrial myocardium: a quantitative immunofluorescence study. Circulation 72, 272–279 (1985).
  Medline CASGoogle Scholar
• 3 Mercadier JJ, de la Bastie D, Menasche P et al. Alpha-myosin heavy chain isoform and atrial size in patients with various types of mitral valve dysfunction: a quantitative study. J. Am. Coll. Cardiol. 9, 1024–1030 (1987).
  Medline CASGoogle Scholar
• 4 Tsuchimochi H, Sugi M, Kuro-o M et al. Isozymic changes in myosin of human atrial myocardium induced by overload. Immunohistochemical study using monoclonal antibodies. J. Clin. Invest. 74, 662–665 (1984).
  Medline CASGoogle Scholar
• 5 Hasenfuss G, Reinecke H, Studer R et al. Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)- ATPase in failing and nonfailing human myocardium. Circ. Res. 75, 434–442 (1994).
  Medline CASGoogle Scholar
• 6 Kaab S, Barth AS, Margerie D et al. Global gene expression in human myocardium oligonucleotide microarray analysis of regional diversity and transcriptional regulation in heart failure. J. Mol. Med. 82, 308–316 (2004).
  MedlineGoogle Scholar
• 7 Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297 (2004).
  Medline CASGoogle Scholar
• 8 Zernecke A, Bidzhekov K, Noels H et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci. Signal. 2, ra81 (2009).
  MedlineGoogle Scholar
• 9 Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell. Biol. 9, 654–659 (2007).
  Medline CASGoogle Scholar
• 10 Arroyo JD, Chevillet JR, Kroh EM et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl Acad. Sci. USA 108, 5003–5008 (2011).
  Medline CASGoogle Scholar
• 11 Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 13, 423–433 (2011).
  Medline CASGoogle Scholar
• 12 Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105, 10513–10518 (2008).
  Medline CASGoogle Scholar
• 13 Lawrie CH, Gal S, Dunlop HM et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 141, 672–675 (2008).
  MedlineGoogle Scholar
• 14 Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18, 997–1006 (2008).
  Medline CASGoogle Scholar
• 15 Tijsen AJ, Creemers EE, Moerland PD et al. MiR423–5p as a circulating biomarker for heart failure. Circ. Res. 106, 1035–1039 (2010).
  Medline CASGoogle Scholar
• 16 Marsit CJ, Eddy K, Kelsey KT. MicroRNA responses to cellular stress. Cancer Res. 66, 10843–10848 (2006).
  Medline CASGoogle Scholar
• 17 Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 113, 25–36 (2003).
  Medline CASGoogle Scholar
• 18 Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 303, 83–86 (2004).
  Medline CASGoogle Scholar
• 19 He L, Thomson JM, Hemann MT et al. A microRNA polycistron as a potential human oncogene. Nature 435, 828–833 (2005).
  Medline CASGoogle Scholar
• 20 Santulli G, Totary-Jain H. Tailoring mTOR-based therapy: molecular evidence and clinical challenges. Pharmacogenomics 14(12), 1517–1526 (2013).
  CASGoogle Scholar
• 21 Volinia S, Calin GA, Liu CG. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103, 2257–2261 (2006).
  Medline CASGoogle Scholar
• 22 Calin GA, Ferracin M, Cimmino A et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353, 1793–1801 (2005).• Seminal study showing the importance of miRNAs in chronic lymphocytic leukemia.
  Medline CASGoogle Scholar
• 23 Bloomston M, Frankel WL, Petrocca F et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297, 1901–1908 (2007).
  Medline CASGoogle Scholar
• 24 Schetter AJ, Leung SY, Sohn JJ et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299, 425–436 (2008).
  Medline CASGoogle Scholar
• 25 van Rooij E, Sutherland LB, Liu N et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl Acad. Sci. USA 103, 18255–18260 (2006).  • Thorough paper illustrating the importance of miRNAs in left ventricular hypertrophy and heart failure.
  Medline CASGoogle Scholar
• 26 Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ. Res. 100, 416–424 (2007).
  Medline CASGoogle Scholar
• 27 Thum T, Galuppo P, Wolf C et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 116, 258–267 (2007).
  Medline CASGoogle Scholar
• 28 Heerdt PM, Holmes JW, Cai B et al. Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure. Circulation 102, 2713–2719 (2000).
  Medline CASGoogle Scholar
• 29 Lowes BD, Gilbert EM, Abraham WT et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N. Engl. J. Med. 346, 1357–1365 (2002).
  Medline CASGoogle Scholar
• 30 Sardu C, Marfella R, Santulli G . . . . Impact of diabetes mellitus on the clinical response to cardiac resynchronization therapy in elderly people. J. Cardiovasc Transl Res. 7, 362–368 (2014).
  MedlineGoogle Scholar
• 31 Vanderheyden M, Mullens W, Delrue L et al. Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J. Am. Coll. Cardiol. 51(2), 129–136 (2008).
  Medline CASGoogle Scholar
• 32 Meyer M, Schillinger W, Pieske B et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 92, 778–784 (1995).
  Medline CASGoogle Scholar
• 33 Kogler H, Schott P, Toischer K et al. Relevance of brain natriuretic peptide in preload-dependent regulation of cardiac sarcoplasmic reticulum Ca²⁺ ATPase expression. Circulation 113, 2724–2732 (2006).
  MedlineGoogle Scholar
• 34 White AJ, Arasaratnam D, Elliott DA, Kaye DM. Cellular reprogramming: a new avenue to cardiac regeneration? Circ. Heart Fail. 6(5), 1102–1107 (2013).
  MedlineGoogle Scholar
• 35 Ramani R, Vela D, Segura A et al. A micro-ribonucleic acid signature associated with recovery from assist device support in 2 groups of patients with severe heart failure. J. Am. Coll. Cardiol. 58(22), 2270–2278 (2011).
  MedlineGoogle Scholar
• 36 Marfella R, Di Filippo C, Potenza N et al. Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders. Eur. J. Heart Fail. 15, 1277–1288 (2013).
  Medline CASGoogle Scholar
• 37 Boettger T, Beetz N, Kostin S, Schneider J, Krüger M, Hein L, Braun T. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the miR143/145 gene cluster. J. Clin. Invest. 119, 2634–2647 (2009).
  Medline CASGoogle Scholar
• 38 Cheng Y, Liu X, Yang J et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ. Res. 105, 158–166 (2009).
  Medline CASGoogle Scholar
• 39 Cordes KR, Sheehy NT, White MP et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 460, 705–710 (2009).
  Medline CASGoogle Scholar
• 40 Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111, 2837–2849 (2005).
  MedlineGoogle Scholar
• 41 Lee EJ, Gusev Y, Jiang J et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer 120(5), 1046–1054 (2007).
  Medline CASGoogle Scholar
• 42 Andreka P, Zang J, Dougherty C, Slepak TI, Webster KA, Bishopric NH. Cytoprotection by Jun kinase during nitric oxide-induced cardiac myocyte apoptosis. Circ. Res. 88(3), 305–312 (2001).
  Medline CASGoogle Scholar
• 43 Porrello ER. MicroRNAs in cardiac development and regeneration. Clin. Sci. (Lond.) 125(4), 151–166 (2013).
  Medline CASGoogle Scholar
• 44 Papoutsidakis N, Deftereos S, Kaoukis A et al. MicroRNAs and the heart: small things do matter. Curr. Top. Med. Chem. 13(2), 216–230 (2013).
  Medline CASGoogle Scholar
• 45 Santulli G, Iaccarino G, De Luca N, Trimarco B, Condorelli G. Atrial fibrillation and microRNAs. Front. Physiol. 5, 15 (2014).
  MedlineGoogle Scholar
• 46 Liu L, Zhang G, Liang Z et al. MicroRNA-15b enhances hypoxia/reoxygenation-induced apoptosis of cardiomyocytes via a mitochondrial apoptotic pathway. Apoptosis 19(1), 19–29 (2014).
  Medline CASGoogle Scholar
• 47 Romero DG, Plonczynski MW, Carvajal CA, Gomez-Sanchez EP, Gomez-Sanchez CE. Microribonucleic acid-21 increases aldosterone secretion and proliferation in H295R human adrenocortical cells. Endocrinology 149(5), 2477–2483 (2008).
  Medline CASGoogle Scholar
• 48 Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9, 653–660 (2003).
  Medline CASGoogle Scholar
• 49 Ji R, Cheng Y, Yue J et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ. Res. 100, 1579–1588 (2007).
  Medline CASGoogle Scholar
• 50 Romero DG, Plonczynski MW, Carvajal CA, Gomez-Sanchez EP, Gomez-Sanchez CE. Microribonucleic acid-21 increases aldosterone secretion and proliferation in H295R human adrenocortical cells. Endocrinology 149, 2477–2483 (2008).
  Medline CASGoogle Scholar
• 51 Andreka P, Nadhazi Z, Muzes G et al. Possible therapeutic targets in cardiac myocyte apoptosis. Curr. Pharm. Des. 10(20), 2445–2461 (2004).
  Medline CASGoogle Scholar
• 52 Latronico MV, Catalucci D, Condorelli G. Emerging role of microRNAs in cardiovascular biology. Circ. Res. 101(12), 1225–1236 (2007).
  Medline CASGoogle Scholar
• 53 Santulli G, Ciccarelli M, Palumbo G et al. In vivo properties of the proangiogenic peptide QK. J. Transl. Med. 8(7), 41 (2009).
  Google Scholar
• 54 Mann DL. MicroRNAs and the failing heart. N. Engl. J. Med. 356, 2644–2645 (2007).
  Medline CASGoogle Scholar
• 55 Manzano M, Shamulailatpam P, Raja AN, Gottwein E. Kaposi’s Sarcoma-associated herpesvirus encodes a mimic of cellular miR-23. J. Virol. 87(21), 11821–11830 (2013).
  Medline CASGoogle Scholar
• 56 Zhu SM, Si ML, Wu HL, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem. 282, 14328–14336 (2007).
  Medline CASGoogle Scholar
• 57 Bishopric NH, Andreka P, Slepak T, Webster KA. Molecular mechanisms of apoptosis in the cardiac myocyte. Curr. Opin. Pharmacol. 1(2), 141–150 (2001).
  Medline CASGoogle Scholar
• 58 Guerra S, Leri A, Wang X et al. Myocyte death in the failing human heart is gender dependent. Apoptosis is initiated by myocardial ischemia and executed during reperfusion. Circ. Res. 85(9), 856–866 (1999).
  Medline CASGoogle Scholar
• 59 Bridge G, Monteiro R, Henderson S et al. The microRNA-30 family targets DLL4 to modulate endothelial cell behavior during angiogenesis. Blood 120(25), 5063–5072 (2012).
  Medline CASGoogle Scholar
• 60 van Rooij E, Sutherland LB, Liu N, Williams AH et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl Acad. Sci. USA 103, 18255–18260 (2006).
  Medline CASGoogle Scholar
• 61 Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res. 67(19), 8994–9000 (2007).
  Medline CASGoogle Scholar
• 62 Chan JA, Krichevsky AM, Kosik KS. microRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65(14), 6029–6033 (2005).
  Medline CASGoogle Scholar
• 63 Karunakaran D, Rayner KJ. MicroRNAs in cardiovascular health: from order to disorder. Endocrinology 154(11), 4000–4009 (2013).
  Medline CASGoogle Scholar
• 64 Melkman-Zehavi T, Oren R, Kredo-Russo S et al. miRNAs control insulin content in pancreatic beta-cells via downregulation of transcriptional repressors. EMBO J. 30, 835–845 (2011).
  Medline CASGoogle Scholar
• 65 Lal A, Pan Y, Navarro F et al. miR-24-mediated downregulation of H2AX suppresses DNA repair in terminally differentiated blood cells. Nat. Struct. Mol. Biol. 16, 492–498 (2009).
  Medline CASGoogle Scholar
• 66 Chan MC, Hilyard AC, Wu C et al. Molecular basis for antagonism between PDGF and the TGFbeta family of signalling pathways by control of miR-24 expression. EMBO J. 29, 559–573 (2010).
  Medline CASGoogle Scholar
• 67 Dai Y, Khaidakov M, Wang X. MicroRNAs involved in the regulation of postischemic cardiac fibrosis. Hypertension 61(4), 751–756 (2013).
  Medline CASGoogle Scholar
• 68 Landgraf P, Rusu M, Sheridan R et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129, 1401–1414 (2007).
  Medline CASGoogle Scholar
• 69 Fiedler J, Jazbutyte V, Kirchmaier BC et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 124, 720–730 (2011).
  Medline CASGoogle Scholar
• 70 Finn NA, Eapen D, Manocha P, Coronary heart disease alters intercellular communication by modifying microparticle-mediated microRNA transport. FEBS Lett. 587(21), 3456–3463 (2013).
  Medline CASGoogle Scholar
• 71 Zhao B, Zhu Y, Cui K, Gao J, Yu F, Chen L, Li S. Expression and significance of PTEN and miR-92 in hepatocellular carcinoma. Mol. Med. Rep. 7(5), 1413–1416 (2013).
  Medline CASGoogle Scholar
• 72 Romilda C, Marika P, Alessandro S et al. Oxidative DNA damage correlates with cell immortalization and miR-92 expression in hepatocellular carcinoma.BMC Cancer 15(12), 177 (2012).
  Google Scholar
• 73 Sengul A, Santisuk R, Xing W, Kesavan C. Systemic administration of an antagomir designed to inhibit miR-92, a regulator of angiogenesis, failed to modulate skeletal anabolic response to mechanical loading. Physiol. Res. 62(2), 221–226 (2013).
  Medline CASGoogle Scholar
• 74 Santulli G, D’Ascia C. Atrial remodelling in echocardiographic super-responders to cardiac resynchronization therapy. Heart 98(6), 517 (2012).
  MedlineGoogle Scholar
• 75 van Rooij E, Sutherland LB, Thatcher JE et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl Acad. Sci. USA 105, 13027–13032 (2008). • Important report describing the pivotal role of miRNA-29 in the pathophysiology of myocardial infarction.
  Medline CASGoogle Scholar
• 76 Olson EN. A decade of discoveries in cardiac biology. Nat. Med. 10, 467–474 (2004).
  Medline CASGoogle Scholar
• 77 Sorriento D, Santulli G, Fusco A, Anastasio A, Trimarco B, Iaccarino G. Intracardiac injection of AdGRK5-NT reduces left ventricular hypertrophy by inhibiting NF-kappaB-dependent hypertrophic gene expression. Hypertension 56, 696–704 (2010).
  Medline CASGoogle Scholar
• 78 Santulli G, Cipolletta E, Sorriento D et al. CaMK4 gene deletion induces hypertension. J. Am. Heart Assoc. 1, e001081 (2012).
  MedlineGoogle Scholar
• 79 Allegra D, Bilan V, Garding A et al. Defective DROSHA processing contributes to downregulation of miR-15/-16 in chronic lymphocytic leukemia leukemia. Leukemia 28(1), 98–107 (2013).
  MedlineGoogle Scholar
• 80 Small EM, Frost RJ, Olson EN. MicroRNAs add a new dimension to cardiovascular diseaseMicroRNAs add a new dimension to cardiovascular disease. Circulation 121, 1022–1032 (2010).
  MedlineGoogle Scholar
• 81 Nass RD, Aiba T, Tomaselli GF, Akar FG. Mechanisms of disease: ion channel remodeling in the failing ventricle. Nat. Clin. Pract. Cardiovasc. Med. 5, 196–207 (2008).
  Medline CASGoogle Scholar
• 82 Zicha S, Fernandez-Velasco M, Lonardo G, L’Heureux N, Nattel S. Sinus node dysfunction and hyperpolarization-activated (HCN) channel subunit remodeling in a canine heart failure model. Cardiovasc. Res. 66, 472–481 (2005).
  Medline CASGoogle Scholar
• 83 Dang X, Ma A, Yang L et al. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genet. 205(3), 113–123 (2012).
  Medline CASGoogle Scholar
• 84 Icli B, Wara AK, Moslehi J et al. MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. Circ. Res. 113(11), 1231–1241 (2013).
  Medline CASGoogle Scholar
• 85 Luo X, Pan Z, Shan H. MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J. Clin. Invest. 123(5), 1939–1951 (2013).
  Medline CASGoogle Scholar
• 86 Lin CC, Lin CC, Lin JL et al. Activation of the calcineurin-nuclear factor of activated T-cell signal transduction pathway in atrial fibrillation. Chest 126(6), 1926–1932 (2004).
  Medline CASGoogle Scholar
• 87 Tavi P, Pikkarainen S, Ronkainen J et al. Pacing induced calcineurin activation controls cardiac Ca²⁺ signaling and gene expression. J. Physiol. 554(Pt 2), 309–320 (2004).
  Medline CASGoogle Scholar
• 88 Divarakan V, Mann DL. The emerging role of microRNAs in cardiac remodelling and heart failure. Circ. Res. 103, 1072–1083 (2008).
  MedlineGoogle Scholar
• 89 Hullinger TG, Montgomery RL, Seto AG et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ. Res. 110(1), 71–81 (2012).
  Medline CASGoogle Scholar
• 90 Montgomery RL, Hullinger TG, Semus HM et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124(14), 1537–1547 (2011).
  Medline CASGoogle Scholar